The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement
The investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its ther...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257124000221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846123380721319936 |
|---|---|
| author | Luigino Calzetta Mario Cazzola Shima Gholamalishahi Paola Rogliani |
| author_facet | Luigino Calzetta Mario Cazzola Shima Gholamalishahi Paola Rogliani |
| author_sort | Luigino Calzetta |
| collection | DOAJ |
| description | The investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its therapeutic efficacy in COPD is lacking. This protocol outlines the first registered systematic review and meta-analysis in PROSPERO to assess the impact of ensifentrine on trough forced expiratory volume in the 1st second (FEV1) and acute exacerbations of COPD. By conducting a rigorous literature search and employing solid methodologies, this endeavour aims to provide robust evidence on the real efficacy of ensifentrine. Anticipated outcomes include a significant improvement in trough FEV1 and a reduction in AECOPD risk among ensifentrine-treated patients compared to controls, corroborating its bronchodilator and anti-inflammatory properties. The meta-analysis expects to reveal consistent results across different trials, enhancing confidence in the findings. Additionally, subgroup analyses may unveil factors influencing the efficacy of ensifentrine, guiding optimal therapeutic strategies. Overall, this protocol holds the potential to inform clinical practice and regulatory decisions, positioning ensifentrine as a valuable addition to COPD management. |
| format | Article |
| id | doaj-art-fa1684766cc34009b4e9ee416809ddf0 |
| institution | Kabale University |
| issn | 2590-2571 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Pharmacology and Drug Discovery |
| spelling | doaj-art-fa1684766cc34009b4e9ee416809ddf02024-12-14T06:32:46ZengElsevierCurrent Research in Pharmacology and Drug Discovery2590-25712024-01-017100195The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statementLuigino Calzetta0Mario Cazzola1Shima Gholamalishahi2Paola Rogliani3Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy; Corresponding author. Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy.Department of Experimental Medicine, Unit of Respiratory Medicine, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Experimental Medicine, Unit of Respiratory Medicine, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Experimental Medicine, Unit of Respiratory Medicine, University of Rome “Tor Vergata”, Rome, ItalyThe investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its therapeutic efficacy in COPD is lacking. This protocol outlines the first registered systematic review and meta-analysis in PROSPERO to assess the impact of ensifentrine on trough forced expiratory volume in the 1st second (FEV1) and acute exacerbations of COPD. By conducting a rigorous literature search and employing solid methodologies, this endeavour aims to provide robust evidence on the real efficacy of ensifentrine. Anticipated outcomes include a significant improvement in trough FEV1 and a reduction in AECOPD risk among ensifentrine-treated patients compared to controls, corroborating its bronchodilator and anti-inflammatory properties. The meta-analysis expects to reveal consistent results across different trials, enhancing confidence in the findings. Additionally, subgroup analyses may unveil factors influencing the efficacy of ensifentrine, guiding optimal therapeutic strategies. Overall, this protocol holds the potential to inform clinical practice and regulatory decisions, positioning ensifentrine as a valuable addition to COPD management.http://www.sciencedirect.com/science/article/pii/S2590257124000221 |
| spellingShingle | Luigino Calzetta Mario Cazzola Shima Gholamalishahi Paola Rogliani The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement Current Research in Pharmacology and Drug Discovery |
| title | The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement |
| title_full | The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement |
| title_fullStr | The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement |
| title_full_unstemmed | The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement |
| title_short | The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement |
| title_sort | novel inhaled dual pde3 and pde4 inhibitor ensifentrine for the treatment of copd a systematic review and meta analysis protocol on trough fev1 and exacerbation according to prisma statement |
| url | http://www.sciencedirect.com/science/article/pii/S2590257124000221 |
| work_keys_str_mv | AT luiginocalzetta thenovelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT mariocazzola thenovelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT shimagholamalishahi thenovelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT paolarogliani thenovelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT luiginocalzetta novelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT mariocazzola novelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT shimagholamalishahi novelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement AT paolarogliani novelinhaleddualpde3andpde4inhibitorensifentrineforthetreatmentofcopdasystematicreviewandmetaanalysisprotocolontroughfev1andexacerbationaccordingtoprismastatement |